‘One size will not fit all’Differences between medical devices and pharmaceuticals: Consequences for the practice of HTA

Chantale Lessard, BPharm, MSc, PhD, DcomplDDirector, Health Economics, Policy & Reimbursement, Medical Affairs, Covidien, MedtronicLecturer, Department of Health Administration, School of Public Health, University of Montreal

CADTH Symposium 2015, Panel Session – Valuing Medical Technologies

2 | Medtronic Confidential

Main differences between medical devices and pharmaceuticals impacting on HTA

3 | Medtronic Confidential

Main differences between medical devices and pharmaceuticals impacting on HTA

4 | Medtronic Confidential

Main differences between medical devices and pharmaceuticals impacting on HTA

5 | Medtronic Confidential

Main differences between medical devices and pharmaceuticals impacting on HTA

6 | Medtronic Confidential

Consequences for the practice of HTA

• Recognition that a ‘one-size-fits-all’ approach to evaluation is inappropriate

• Evaluation approach should be tailored to the medical device• Based on the type, context of practice, indication, and use

• View the HTA for medical devices as an iterative process• Information about clinical efficacy and cost-effectiveness

is necessary but not sufficient– Understanding the social, ethical, professional and

organizational implications is also vital

• Development of innovative HTA methods for medical devices will require the engagement of industry, and of decision- and policy-makers

7 | Medtronic Confidential

Contact

Chantale Lessard, BPharm, MSc, PhD, DcomplD Director, Health Economics, Policy & ReimbursementMedical Affairs, Covidien

Medtronic8455, route TranscanadienneVille St-Laurent, Québec, H4S 1Z1

chantale.lessard@covidien.com